Bagsværd, Denmark Saturday, September 21, 2024, 15:00 Hrs [IST] ...

Novo Nordisk receives a positive opinion from the CHMP for a label update of Wegovy to reflect reduced heart failure symptoms ...

Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart ...

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended an update to Novo ...

BAGSVAERD, Denmark I 19, 2024 I Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human ...

Novo Nordisk said that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a ...

The weight-loss jab Wegovy has been hailed as an “absolute game-changer” after a new study showed that it relieved symptoms ...

Semaglutide, the popular anti-obesity medication originally developed to treat diabetes, continues to show cardiovascular ...

In addition to improving heart failure symptoms, finerenone reduced the onset of new type 2 diabetes in patients with mildly ...

Another concern with all GLP-1 receptor agonist trials is weight loss leading to unmasking of treatment assignment, potentially confounding effects on KCCQ and 6MWD in the STEP-HFpEF trials. The ...

HuMAIN-HFpEF Trial Late Breaking Clinical Research showcases novel results of major randomized trials and rapidly evolving research. Leaders of the field will serve as discussants, presenting ...

In patients with HFpEF, spironolactone decreases all-cause mortality. Spironolactone is associated with reduced all-cause mortality among patients with heart failure with preserved ejection ...